SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Ardelyx, Inc. Common Stock and Sets a Lead Plaintiff Deadline of November 16, 2026

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired common stock of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) between January 13, 2025, and August 6, 2026, inclusive. You are hereby notified that the class action lawsuit Broadwater v. Ardelyx, Inc., et al. (Case No. 1:26-cv-14270) has been commenced in the United States District Court for the District of Massachusetts. To get more information go to:

https://zlk.com/cases/ardx-class-action-lawsuit-ardx

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material facts concerning the true state of Ardelyx’s commercial performance and growth prospects for XPHOZAH and IBSRELA, and in particular the increasing payer-related access and reimbursement barriers affecting patient access, more stringent prior authorization requirements and step edit requirements that slowed new-patient starts and delayed prescription fulfillment.

On August 6, 2026, Ardelyx issued a press release a reduction in its full-year 2026 IBSRELA revenue guidance and withdrawal of its long-term XPHOZAH revenue guidance. Management attributed the reduction on significantly increased payer utilization-management processes that restricted patient access to IBSRELA and slowed new-patient starts. Further, Defendants withdrew their long-term XPHOZAH revenue guidance due to “evolving market dynamics” and uncertainty regarding future growth projections.

On this news, the price of Ardelyx’s common stock declined dramatically. From a closing market price of $4.87 per share on August 6, 2026, Ardelyx’s stock price fell to $4.00 per share on August 7, 2026, a decline of about 18% in the span of just a single day.

“Our firm is committed to ensuring that investors receive full compensation for losses caused by corporate misrepresentations,” said Joseph E. Levi, a partner at Levi & Korsinsky. “We encourage ARDX shareholders to step forward before the November 16, 2026 deadline so we can pursue justice on their behalf.”

If you suffered a loss in ARDX common stock, you have until November 16, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP  
Joseph E. Levi, Esq. 
Ed Korsinsky, Esq. 
33 Whitehall Street, 27th Floor 
New York, NY 10004 
jlevi@levikorsinsky.com  
Tel: (212) 363-7500 
Fax: (212) 363-7171 
www.zlk.com